Sars Cov 2 clinical trials

Explore recruiting sars cov 2 clinical trials.

Recruiting sars cov 2 studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Sars Cov 2 trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

C4671026-A PHASE 2/3, INTERVENTIONAL SAFETY, PHARMACOKINETICS, AND EFFICACY, OPEN-LABEL, MULTI-CENTER, SINGLE-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332 (NIRMATRELVIR)/RITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID-19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE

Bulgaria, Hungary

Phase II and Phase III (Integrated) EU CTIS Study details

Achieving viral CLEARance in immunocompromised participants with long-term persistence of SARS-CoV-2 - an open-label randomized trial (CLEAR)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

SAFETY AND EFFICACY OF A 10-DAY COURSE OF REMDESIVIR TO PREVENT SEVERE COVID-19 IN ASYMPTOMATIC OR PAUCISYMPTOMATIC SARS-COV-2-POSITIVE KIDNEY TRANSPLANT RECIPIENTS: A SINGLE-ARM PROOF-OF-CONCEPT INTERVENTIONAL TRIAL

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression

Italy, Poland, Spain, Finland, Germany, Romania +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

CONCOMITANT ADMINISTRATION OF LICENSED VACCINES AGAINST COVID-19 AND FLU WITH OR WITHOUT MF59 ADJUVANT: A MULTI-CENTRE, RANDOMIZED, SINGLE-BLIND CLINICAL TRIAL TO ASSESS IMMUNOGENICITY IN ADULTS AGED 65 AND OVER

Belgium, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

TURN-COVID Biobank: The Dutch cohort study tor the evaluation of the use of neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Sars Cov 2 trials by city

Sars Cov 2 in Toronto Sars Cov 2 in Vancouver Sars Cov 2 in Montreal Sars Cov 2 in Calgary Sars Cov 2 in Edmonton Sars Cov 2 in Ottawa Sars Cov 2 in Winnipeg Sars Cov 2 in Quebec City Sars Cov 2 in Hamilton Sars Cov 2 in Kitchener Sars Cov 2 in London Sars Cov 2 in Halifax Sars Cov 2 in New York Sars Cov 2 in Los Angeles Sars Cov 2 in Chicago Sars Cov 2 in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease